Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

被引：1

作者：

Rueda, Antonio ^{[1
]}

Calvo, Virginia ^{[2
]}

Casanova, Maria ^{[1
]}

Rodriguez-Abreu, Delvys ^{[3
]}

Aguiar, David ^{[4
]}

Llanos, Marta ^{[5
]}

Alvarez, Ruth ^{[6
]}

Martinez-Banaclocha, Natividad ^{[7
]}

Alfaro, Jesus ^{[8
]}

Quero, Cristina ^{[9
]}

Blasco, Ana ^{[10
]}

de la Cruz Merino, Luis ^{[11
]}

Herrero, Joaquin ^{[12
]}

Garcia-Arroyo, Francisco R. ^{[13
]}

Provencio, Mariano ^{[2
]}

机构：

[1] Hosp Costa Sol, Marbella, Spain

[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain

[3] Hosp Insular, Las Palmas Gran Canaria, Las Palmas, Spain

[4] Hosp Dr Negrin, Las Palmas Gran Canaria, Las Palmas, Spain

[5] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain

[6] Hosp Virgen Salud, Toledo, Spain

[7] Hosp Gen Univ Elche, Alicante, Spain

[8] Oncologikoa, Donostia San Sebastian, Spain

[9] Hosp Univ Gen & Virgen Victoria, Malaga, Spain

[10] Hosp Gen Univ, Valencia, Spain

[11] Hosp Virgen Macarena, Seville, Spain

[12] Hosp Gen Univ Alicante, Alicante, Spain

[13] Complexo Hosp Univ Pontevedra, Pontevedra, Spain

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期

关键词：

NON-HODGKIN-LYMPHOMA; INDOLENT B-CELL; PLUS RITUXIMAB; MANTLE-CELL; 1ST-LINE TREATMENT; OPEN-LABEL; RELAPSED INDOLENT; MULTICENTER; OBINUTUZUMAB; THERAPY;

D O I：

10.1080/10428194.2018.1542147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1576 / 1579

页数：4

共 50 条

[1] RITUXIMAB-BENDAMUSTINE AS FIRST LINE OF TREATMENT IN PATIENTS WITH FOLLICULAR LYMPHOMA. EXPERIENCE OF ONE CENTER
Melian Haridian, De la Nuez
Henriquez Hugo, Luzardo
Cabrera Alexia, Suarez
Gonzalez Paula, Fernandez-Caldas
Cruz Naylen, Cruz
Borrego Asuncion, Borrero
Juan Francisco, Lopez Rodriguez
Curbelo Alejandro, Morales
De La Cruz Marcos, Cabezas
Maria Teresa, Gomez Casares
HAEMATOLOGICA, 2021, 106 (10) : 296 - 297
[2] Rituximab-Bendamustine in First Line Treatment of Patients with Follicular Lymphoma. Results of Prospective Multicenter Study
Ekaterina, Nesterova
Kravchenko, Sergey K.
Kovrigina, Alla M.
Plastinina, Lubov V.
Mangasarova, Yana K.
Gorenkova, Liliya
Vorobyev, Vladimir
Mariin, Dmitriy
Baryakh, Elena A.
Polyakov, Yuriy
Zeynalova, Pervin
Volodicheva, Elena
Glonina, Nataliya
Savchenko, Valeriy G.
BLOOD, 2017, 130
[3] Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
Zaja, Francesco
Ferrero, Simone
Stelitano, Caterina
Ferrari, Angela
Salvi, Flavia
Arcari, Annalisa
Musuraca, Gerardo
Botto, Barbara
Spina, Michele
Cellini, Claudia
Patti, Caterina
Liberati, Anna M.
Minotto, Claudia
Pileri, Stefano A.
Ceccarelli, Manuela
Volpetti, Stefano
Ferranti, Antonella
Drandi, Daniela
Montechiarello, Elisa
Ladetto, Marco
Carmichael, James
Fanin, Renato
HAEMATOLOGICA, 2017, 102 (05) : E203 - E206
[4] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
Hess, Georg
Keller, Ulrich
Atta, Johannes
Buske, Christian
Borchmann, Peter
Medler, Christoph
Witzens-Harig, Mathias
Dreyling, Martin H.
BLOOD, 2011, 118 (21) : 1159 - 1159
[5] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial
Hess, Georg
Keller, Ulrich
Atta, Johannes
Bitz, Ulrich
Lerchenmueller, Christian
Karola, Wagner
Medler, Christoph
Ruckes, Christian
Witzens-Harig, Mathias
Huebel, Kai
LaRosee, Paul
Dreyling, Martin H.
BLOOD, 2015, 126 (23)
[6] Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
Hess, Georg
Wagner, Karola
Keller, Ulrich
La Rosee, Paul
Atta, Johannes
Huebel, Kai
Lerchenmueller, Christian
Schoendube, Daniel
Witzens-Harig, Mathias
Ruckes, Christian
Medler, Christoph
van Oordt, Christina
Klapper, Wolfram
Theobald, Matthias
Dreyling, Martin
HEMASPHERE, 2020, 4 (03):
[7] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
Flinn, Ian W.
Mainwaring, Mark
Peacock, Nancy
Shipley, Dianna
Arrowsmith, Edward
Savona, Michael R.
Hainsworth, John D.
Berdeja, Jesus G.
BLOOD, 2012, 120 (21)
[8] Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Penalver, Francisco-Javier
Marquez, Jose-Antonio
Duran, Soledad
Giraldo, Pilar
Martin, Alejandro
Montalban, Carlos
Sancho, Juan-Manuel
Ramirez, Maria-Jose
Terol, Maria-Jose
Capote, Francisco-Javier
Gutierrez, Antonio
Sanchez, Blanca
Lopez, Andres
Salar, Antonio
Rodriguez-Caravaca, Gil
Canales, Miguel
Caballero, Maria-Dolores
Bello Lopez, Jose Luis
Carbonell, Felix
Ferrer Bordas, Secundino
Font Lopez, Patricia
Perez Persona, Ernesto
Lopez Guillermo, Armando
Hernandez Martin, Roberto
Ramon Mayans, Jose
Palomera, Luis
Perez Ceballos, Elena
Queizan Hernandez, Jose Antonio
Riaza Grau, Rosalia
de la Cruz, Fatima
Sanchez Salinas, Andres
CANCER MEDICINE, 2019, 8 (16): : 6955 - 6966
[9] A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
Luminari, Stefano
Goldaniga, Maria
Cesaretti, Marina
Orsucci, Lorella
Tucci, Alessandra
Pulsoni, Alessandro
Salvi, Flavia
Arcaini, Luca
Carella, Angelo Michele
Tedeschi, Alessandra
Pinto, Antonello
Stelitano, Caterina
Baldini, Luca
LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 880 - 887
[10] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
M. Pouyiourou
A. Meyer
A. Stroux
A. Viardot
P. La Rosée
G. Maschmeyer
D. Kämpfe
C. Kahl
V. Vucinic
A. Monecke
C. Hirt
T. Weber
J. Meissner
M. Witzens-Harig
S. Böttcher
H. Schmalenberg
R. Marks
G. Prange-Krex
F. Kroschinsky
E. Hauf
U. Keller
K. Koch
W. Klapper
M. Herold
Christian W. Scholz
Annals of Hematology, 2020, 99 : 2821 - 2829

← 1 2 3 4 5 →